Entry by Other Companies Following Patent Expirations and Other Events
First written in FY2017. 9 of 15 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.
14 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「The Group also ensures the appropriate protection and management of know-how in accordance with its confidential information management regulations.」
In addition to measures addressing the risks of patent expiry and infringement of third-party rights, the company specifies the management of confidential information concerning know-how, making its intellectual property protection measures more concrete. - FY2023MitigatedAnnual report
「To prepare for these risks, the Group conducts thorough investigations and examinations from the product development stage, in accordance with its intellectual property management regulations, regarding the possibility of infringing third-party intellectual property rights and the possibility of securing rights to new inventions and other developments.」
In response to the risks of entry by other companies following patent expiry and infringement of third-party rights, the company explicitly states that it investigates potential infringement and considers securing rights from the product development stage. - FY2022ReframedAnnual report
「In addition, if a third party brings a claim alleging that the Group has infringed its intellectual property rights, the Group may incur not only litigation costs but also damages and an injunction against manufacturing and sales. If this results in the loss of the market itself, the Group's business development and performance may be materially affected.」
The scope has been expanded from the risk of entry by other companies following patent expiry to intellectual property risks, including litigation and injunctions against manufacturing and sales arising from infringement of third-party rights. - FY2022-Q2RestatedAnnual report
「No new business or other risks arose during the six-month cumulative period under review. There were also no material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter of the current consolidated fiscal year. There were also no significant changes to the business or other risks described in the securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2021-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the six-month cumulative period under review. There were also no material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter of the current consolidated fiscal year. There were also no significant changes to the business or other risks described in the securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2020-Q3RestatedAnnual report
「There have been no material changes in the business and other risks described in the securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2020-Q1RestatedAnnual report
「There have been no material changes in the business and other risks described in the securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2019The ratio of products covered by patents and other rights declinedAnnual report
「The Group files nearly 50 patent and other applications each year through its proprietary development activities and works to develop new products. On a standalone basis, products covered by patents and other rights account for 56.6% of net sales. However, there is also an inherent risk that other companies will enter the market following the expiration of such rights.」
While continuing to file approximately 50 applications each year and identify the risk of entry by other companies following rights expiry, the ratio of products covered by patents and other rights fell from 64.5% in the previous fiscal year to 56.6%. - FY2019-Q3RestatedAnnual report
「There have been no material changes in the business and other risks described in the securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2019-Q2RestatedAnnual report
「No new business or other risks arose during the six-month cumulative period under review. There were also no material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
The company states that there have been no material changes in the risk of entry by other companies following patent expiry and other events. - FY2018The ratio of products covered by patents and other rights declinedAnnual report
「The Group files nearly 50 patent and other applications each year through its proprietary development activities and works to develop new products. On a standalone basis, products covered by patents and other rights account for 64.5% of net sales. However, there is also an inherent risk that other companies will enter the market following the expiration of such rights.」
Although the ratio of products covered by patents and other rights fell from 66.4% in the previous period to 64.5%, the company continues to file approximately 50 applications each year and identify the risk of entry by other companies following rights expiry. - FY2017First statedAnnual report
「The Group files nearly 50 patent and other applications each year through its proprietary development activities and works to develop new products. On a standalone basis, products covered by patents and other rights account for 66.4% of net sales. However, there is also an inherent risk that other companies will enter the market following the expiration of such rights.」
Products covered by patents and other rights account for 66.4% of standalone net sales, and the company files approximately 50 applications each year, while identifying entry by other companies following rights expiry as a risk for the first time.